The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Demographics === One study conducted by investigators at the University of North Carolina Chapel Hill looked into donated sperm utilization within the United States from 1995 to 2017. Cross-sectional studies recorded that an estimated 170,701 individuals during 1995 used donated sperm, while the 2011 to 2013 cohort had a decreased amount of donated sperm use of 37,385. Most recently, in the 2015 to 2017 cohort, 440,986 individuals were reported to use donated sperm. When looking at 200,197 individuals across 2011–2017, 76% had a 4-year college degree or further while 24% had high school or 2-year college degree. In terms of household percent of poverty, 71% of the sperm bank users were at or above 400% of the household poverty level while only 11% were between 200 and 399% of the household poverty levels. Although the household income levels were not explicit, there seems to be an obvious trend that higher education level attainment (such as finishing college or higher) and being at much higher income level above the household poverty levels were the common tendencies in the sperm bank users.
=== Variation === The size of the pancreas varies considerably. Several anatomical variations exist, relating to the embryological development of the two pancreatic buds. The pancreas develops from these buds on either side of the duodenum. The ventral bud rotates to lie next to the dorsal bud, eventually fusing. In about 10% of adults, an accessory pancreatic duct may be present if the main duct of the dorsal bud of the pancreas does not regress; this duct opens into the minor duodenal papilla. If the two buds themselves, each having a duct, do not fuse, a pancreas may exist with two separate ducts, a condition known as a pancreas divisum. This condition has no physiologic consequence. If the ventral bud does not fully rotate, an annular pancreas may exist, where the pancreas encircles part or all of the duodenum. This may be associated with duodenal atresia.
Teleosts have four major life stages: the egg, the larva, the juvenile and the adult. Species may begin life in a pelagic environment or a demersal environment (near the seabed). Most marine teleosts have pelagic eggs, which are light, transparent and buoyant with thin envelopes. Pelagic eggs rely on the ocean currents to disperse and receive no parental care. When they hatch, the larvae are planktonic and unable to swim. They have a yolk sac attached to them which provides nutrients. Most freshwater species produce demersal eggs which are thick, pigmented, relatively heavy and able to stick to substrates. Parental care is much more common among freshwater fish. Unlike their pelagic counterparts, demersal larvae are able to swim and feed as soon as they hatch. Larval teleosts often look very different from adults, particularly in marine species. Some larvae were even considered different species from the adults. Larvae have high mortality rates, most die from starvation or predation within their first week. As they grow, survival rates increase and there is greater physiological tolerance and sensitivity, ecological and behavioural competence. At the juvenile stage, a teleost looks more like its adult form. At this stage, its axial skeleton, internal organs, scales, pigmentation and fins are fully developed. The transition from larvae to juvenile can be short and fairly simple, lasting minutes or hours as in some damselfish, while in other species, like salmon, squirrelfish, gobies and flatfishes, the transition is more complex and takes several weeks to complete.
Wellcome established its second corporate brand, First Choice, with a product range of over 1,000 items. With prices at 20–30% less than competitive international brands, it is a well-known brand in Hong Kong. A HK$400 million investment, "Wellcome Fresh Food Centre" was opened in 1998, occupying an area of 161,000 sq. ft. In the 1990s, Wellcome Hong Kong to become the first to use the UPC system in Hong Kong supermarkets, offers a more efficient and more convenient payment services. According to the report of 2004–2008, Wellcome supermarkets and thus increase the number of branches. Wellcome introduced the "Vote For Your Favourite Brand" campaign in 2000 and soon opened a superstore at Tuen Mun Town Plaza. The Wellcome superstore introduced a new "one-stop" shopping service, embracing the concepts of both wet market and grocery shop under one roof. Wellcome also began its double refund offer with lowest price guarantee by doubling the difference back to customers. Wellcome unveiled its Stanley store in January 2003. It is the first supermarket located inside a 100-year-old historical building – the old Stanley Police Station. In 2014, Wellcome Taiwan was found to have used contaminated ingredients in its mushroom and minced pork seasonings, drawing it into the 2014 Taiwan food scandal. Wellcome Taiwan was acquired by Carrefour in 2020. While Wellcome Philippines locations were turned into Robinsons Easymart after Robinsons Retail purchased Rustan's Supercenters.
Sources: en.wikipedia.org
== Causes == It is mainly unknown what causes sJIA. There have been reports of seasonal fluctuations in the incidence of sJIA in some places but not in others. Although it has frequently been claimed that infectious organisms cause the condition to manifest, microbiologic and virologic analyses are unable to pinpoint a single agent as the cause. Since a negative septic screen is required for the diagnosis, sJIA is not an infectious disease by definition. There is evidence that suggests a genetic predisposition plays a role in the etiology of sJIA.
The IDF said that one in five rockets launched by Hezbollah had landed in Lebanese territory and published an infographic showing failed rocket launches into Israel. On 16 December, a soldier from the IDF's 129th Battalion was killed by a Hezbollah drone strike near Margaliot, which also caused a fire in a building. Two other soldiers were injured. Another drone was shot down by the IDF, which also responded to the infiltrations by shelling targets. The IAF later hit several Hezbollah targets inside Lebanon, including rocket launch sites and military infrastructure. On 22 December, two IDF soldiers of the 188th Armored Brigade were killed by a Hezbollah rocket attack in the Shtula area. On the morning of 23 December, IDF aircraft bombed a house in Kfar Kila and intense artillery fire also took place on the outskirts of Deir Mimas The IDF conducted a raid near a UNIFL center along the Khardali River. An Al-Manar cameraman was injured in the eye after an IDF attack on a road in the al-Khardali area where correspondents of MTV and the state-owned National News Agency were also passing. Hezbollah announced that two of their members were killed on that day. On 24 December, senior IRGC general Razi Mousavi was killed by an Israeli airstrike in Damascus. On 26 December, a Hezbollah anti-tank missile hit St. Mary's Greek Orthodox Church in Iqrit, northern Israel. A civilian suffered serious injuries, and when IDF responders arrived at the scene, another missile was fired, injuring nine soldiers.
Intermediate-level waste (ILW) contains higher amounts of radioactivity compared to low-level waste. It generally requires shielding, but not cooling. Intermediate-level wastes includes resins, chemical sludge and metal nuclear fuel cladding, as well as contaminated materials from reactor decommissioning. It may be solidified in concrete or bitumen or mixed with silica sand and vitrified for disposal. As a general rule, short-lived waste (mainly non-fuel materials from reactors) is buried in shallow repositories, while long-lived waste (from fuel and fuel reprocessing) is deposited in geological repository. Regulations in the United States do not define this category of waste; the term is used in Europe and elsewhere. ILW makes up 6% of all radioactive waste volume in the UK.
=== Insulin lispro === Insulin lispro, marketed under the brand name Humalog among others, is a modified form of medical insulin used to treat both type 1 and type 2 diabetes. It is administered subcutaneously through injection or an insulin pump. The effects typically begin within 30 minutes and last for about 5 hours. Sometimes, a longer-acting insulin, such as insulin NPH, is also used. Common side effects include low blood sugar, while more serious side effects may include low blood potassium. It is generally considered safe for use during pregnancy and breastfeeding. It functions similarly to human insulin by increasing glucose uptake in tissues and reducing the amount of glucose produced by the liver in gluconeogenesis. Insulin lispro was first approved for use in the United States in 1996. It is a synthetic analogue of human insulin, created by swapping two amino acids. In 2022, it ranked as the 70th most commonly prescribed medication in the United States, with over 9 million prescriptions. Insulin lispro is available under a generic label from Lilly.
The chemical energy stored in ATP (the bond of its third phosphate group to the rest of the molecule can be broken, allowing more stable products to form, thereby releasing energy for use by the cell) can then be used to drive processes requiring energy, including biosynthesis, locomotion, or transportation of molecules across cell membranes.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.